Welcome to our dedicated page for Intelligent Bio Solutions SEC filings (Ticker: INBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intelligent Bio Solutions Inc. (INBS) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology issuer, Intelligent Bio Solutions uses these filings to report financial results, corporate actions, governance matters and material events related to its non-invasive drug screening and testing solutions.
Investors researching INBS can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, risk factors, financial statements and segment information. These periodic reports describe the Intelligent Fingerprinting Drug Screening System, the company’s consumables-focused revenue model, geographic reach and customer segments in sectors such as construction, manufacturing and engineering, transport and logistics, mining, drug treatment organizations and coroners.
The company also files numerous Form 8-K current reports covering specific developments. Recent 8-K filings describe preliminary and final revenue results, record quarterly revenue driven by cartridge sales, the extension of warrant termination dates, new customer account additions, and updates on regulatory timelines for FDA 510(k) clearance of the Intelligent Fingerprinting Drug Screening System. Other 8-Ks detail stockholder meeting outcomes, amendments to the 2019 Long Term Incentive Plan, and the approval and implementation of a 1-for-10 reverse stock split effective December 15, 2025.
Listing-related disclosures appear in filings that discuss Nasdaq bid price compliance, including the December 15, 2025 deficiency letter noting that the company’s closing bid price had been below $1.00 per share for 30 consecutive business days and granting an initial 180-day compliance period. Additional filings describe equity and warrant transactions, such as private placements and warrant inducement arrangements submitted for stockholder approval under Nasdaq rules.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q and 8-K filings, helping readers quickly understand topics like revenue trends, capital structure changes, equity incentive plan amendments and regulatory updates. Users can also locate information relevant to insider and equity-linked activity by reviewing warrant-related disclosures and stock-based compensation plans discussed in proxy statements and current reports.
By using this INBS filings page, investors and analysts can efficiently monitor how Intelligent Bio Solutions communicates its financial condition, strategic initiatives, governance decisions and listing status to regulators and the market, without needing to manually parse each full-length SEC document.
Intelligent Bio Solutions Inc. furnished a Form 8-K announcing financial results for the fiscal quarter ended September 30, 2025. The results were communicated via a press release attached as Exhibit 99.1. The company stated that the information is furnished, not filed, and will not be incorporated by reference into other filings unless expressly stated.
Intelligent Bio Solutions Inc. (INBS) reported results for the quarter ended September 30, 2025. Revenue was $1,111,797, up from $872,287, with gross profit of $518,291 and an improved gross margin of 46.6%. Government support income was $193,267. Operating expenses rose to $3,711,151, including $2,659,824 in SG&A, $486,169 in development and regulatory costs, and a $261,780 impairment.
The company recorded a net loss of $2,994,992 (loss per share $0.35). Cash and cash equivalents were $1,660,105, with a working capital deficit of $577,705. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern without additional funding.
INBS raised funds via equity: $3,332,646 net from July 2025 warrant inducements and $213,750 net through its ATM program during the quarter. Warrants outstanding totaled 7,935,928. As of November 10, 2025, 9,452,553 common shares were outstanding. Management reported material weaknesses in internal control over financial reporting and disclosed Nasdaq minimum bid price compliance risk.
Intelligent Bio Solutions Inc. furnished an update on business performance, announcing preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1.
The disclosure is presented as information furnished under Item 2.02 and is not deemed “filed” for purposes of the Exchange Act, nor incorporated by reference unless expressly stated.
Intelligent Bio Solutions Inc. announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025. The update was furnished under Item 7.01 (Regulation FD) and accompanied by a press release filed as Exhibit 99.1.
The company listed its common stock under the symbol INBS on the Nasdaq Stock Market LLC. The disclosure was signed by Spiro Sakiris, Chief Financial Officer.
Intelligent Bio Solutions (INBS) reported results from its October 16 annual meeting. Stockholders approved an amendment to the 2019 Long Term Incentive Plan, increasing the share pool by 495,000 to 1,795,000 shares. They also approved, for Nasdaq Listing Rule 5635(d) purposes, the potential issuance of up to 4,147,616 shares upon warrant exercise.
Directors were elected and the appointment of UHY LLP as auditor for the fiscal year ending June 30, 2026 was ratified. Stockholders authorized a reverse stock split within a 1‑for‑2 to 1‑for‑10 range, at the Board’s discretion within 12 months, solely to help regain compliance with the Nasdaq Capital Market minimum bid price requirement. At the meeting, 4,482,941 shares voted, representing approximately 49.65% of the 9,028,712 shares outstanding as of September 11, 2025.
Intelligent Bio Solutions Inc. furnished a current report describing a press release about its regulatory plans. On September 26, 2025, the company announced an update to the timeline for its anticipated FDA 510(k) clearance for using its Intelligent Fingerprinting Drug Screening System to test for the opiate codeine. The press release with further details is attached as an exhibit to the report and is treated as furnished, not filed, under securities law.
INTELLIGENT BIO SOLUTIONS, INC. (INBS) filed an Form 8-K reporting a material event that attaches the Form of Amended Series H-1 Warrant as an exhibit. The filing lists Exhibit 4.1 as the amended warrant form and includes an Inline XBRL cover page data file. The document is signed by Spiro Sakiris, Chief Financial Officer.
The filing notifies stakeholders that the company has documented changes to the Series H-1 warrant in a formal amended warrant agreement, but it does not disclose the economic terms, number of warrants affected, exercise price, expiration, or any related cash or equity effects.
Intelligent Bio Solutions Inc. proxy materials disclose governance and compensation program details including an Insider Trading Policy that forbids hedging transactions by directors, officers and employees and requires compliance with applicable securities laws. The company implemented a Dodd-Frank restatement recoupment (clawback) policy effective October 2, 2023 to recoup erroneously awarded incentive compensation tied to a restatement over a defined lookback period. The filing shows an equity compensation plan with 1,192,655 shares referenced and plan provisions covering stock options, SARs, restricted stock, RSUs, transfer limits, typical vesting practices and a maximum 10-year option term (five years for >10% holders). A reverse stock split amendment is being recommended by the Board for stockholder approval. The largest disclosed shareholder is Alyeska Master Fund, LP with 927,292 shares (9.99%). Executive and director compensation snippets appear (e.g., Spiro Sakiris totals and director fees) and the Plan notes that shares to be issued are not registered under the Securities Act as of the Effective Date.
Intelligent Bio Solutions Inc. is registering up to $1,211,174 of common stock under an at-the-market offering program with Ladenburg Thalmann. The company may sell shares from time to time on Nasdaq, paying Ladenburg a 3% commission, and plans to use net proceeds of up to about $1.064 million primarily for working capital and general corporate purposes.
As of September 17, 2025, common stock outstanding was 9,077,326 shares, with an illustrative post-offering total of 9,936,314 shares if 858,988 shares are sold at $1.41, which would dilute new investors. The company reported cash and cash equivalents of $1,019,909 as of June 30, 2025 and its auditor raised substantial doubt about its ability to continue as a going concern.
Recent FDA interactions add regulatory uncertainty: after a 510(k) submission for its Intelligent Fingerprinting System, the FDA requested additional information on September 12, 2025 that will require a new 510(k) filing, and the company expects to update investors with a revised clearance timeline.
Intelligent Bio Solutions Inc. reported that the FDA has requested additional information on its Intelligent Fingerprinting Drug Screening System, requiring the company to submit a new 510(k) notification. The FDA’s requests were communicated in a letter dated September 12, 2025. The company plans to provide an investor update within the next ten days to outline a revised timeline for potential FDA 510(k) clearance of the drug screening system.
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
What is the market cap of Intelligent Bio Solutions (INBS)?
